BidaskClub downgraded shares of Integra Lifesciences (NASDAQ:IART) from a buy rating to a hold rating in a research report released on Saturday.

A number of other research firms also recently commented on IART. Cantor Fitzgerald reiterated a hold rating and set a $59.00 price objective on shares of Integra Lifesciences in a research note on Tuesday, June 12th. Zacks Investment Research cut shares of Integra Lifesciences from a buy rating to a hold rating in a report on Tuesday, June 26th. Citigroup cut shares of Integra Lifesciences from a buy rating to a neutral rating and increased their target price for the stock from $64.00 to $66.00 in a report on Monday, July 2nd. Oppenheimer set a $74.00 target price on shares of Integra Lifesciences and gave the stock a buy rating in a report on Friday, June 1st. Finally, JPMorgan Chase & Co. increased their target price on shares of Integra Lifesciences from $57.00 to $65.00 and gave the stock a neutral rating in a report on Tuesday, May 22nd. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the stock. Integra Lifesciences presently has a consensus rating of Hold and a consensus target price of $61.38.

NASDAQ IART opened at $58.39 on Friday. Integra Lifesciences has a 12 month low of $41.51 and a 12 month high of $67.50. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.27 and a current ratio of 3.52. The firm has a market cap of $5.35 billion, a price-to-earnings ratio of 30.03, a P/E/G ratio of 1.94 and a beta of 0.57.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 25th. The life sciences company reported $0.60 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.60. Integra Lifesciences had a net margin of 5.10% and a return on equity of 17.43%. The firm had revenue of $366.20 million for the quarter, compared to the consensus estimate of $368.08 million. During the same period in the prior year, the firm posted $0.45 EPS. The firm’s revenue was up 29.8% compared to the same quarter last year. research analysts expect that Integra Lifesciences will post 2.4 EPS for the current fiscal year.

In other Integra Lifesciences news, Director Stuart Essig sold 159,752 shares of the stock in a transaction on Tuesday, July 10th. The shares were sold at an average price of $64.01, for a total transaction of $10,225,725.52. Following the sale, the director now directly owns 1,539,019 shares of the company’s stock, valued at $98,512,606.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel L. Reuvers sold 1,000 shares of the stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $66.97, for a total transaction of $66,970.00. Following the completion of the sale, the vice president now directly owns 25,009 shares in the company, valued at approximately $1,674,852.73. The disclosure for this sale can be found here. Insiders have sold 271,892 shares of company stock worth $17,347,342 over the last three months. 5.10% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. We Are One Seven LLC increased its holdings in shares of Integra Lifesciences by 4,497.1% in the 1st quarter. We Are One Seven LLC now owns 3,218 shares of the life sciences company’s stock worth $178,000 after acquiring an additional 3,148 shares during the period. Zeke Capital Advisors LLC acquired a new stake in shares of Integra Lifesciences in the 2nd quarter worth about $204,000. Coldstream Capital Management Inc. acquired a new stake in shares of Integra Lifesciences in the 1st quarter worth about $207,000. Stanley Laman Group Ltd. acquired a new stake in shares of Integra Lifesciences in the 1st quarter worth about $221,000. Finally, Eagle Boston Investment Management Inc. acquired a new stake in shares of Integra Lifesciences in the 2nd quarter worth about $223,000. 81.99% of the stock is currently owned by institutional investors and hedge funds.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: How Important is Technical Analysis of Stocks

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.